Q2 FY26 Earnings Results
Q2 FY26 earnings, Jul–Sep 2025: 6,052 Indian listed companies have reported; median profit growth is +2.2% on last year, and 114 of 245 companies with analyst estimates beat them. Quarter ended 30 Sep 2025.
Reported
6,052
companies
Profit breadth
51% / 45%
grew / declined · 4,400 comparable
Median sales YoY
+8.9%
across all reporters
Median profit YoY
+2.2%
across all reporters
Beat / missed
114 / 107
of 245 covered
Strongest / weakest
Food Products +22.2%
Forest Materials −33.3%
median profit growth, 10+ reporters
Clear filters 201–269 of 269
| Company | Revenue (₹ Cr) | Profit (₹ Cr) | Per share | 8Q profit | |||||
|---|---|---|---|---|---|---|---|---|---|
| Symbol | Sector | Reported | YoY | QoQ | Reported | YoY | EPS | vs consensus | Trend |
 SANJIVANIPARANTERALLTD | Healthcare | 16 | down−14.5% | down−13.4% | 2 | down−28.7% | 1.34 | No estimate | |
 A D S Diagnostic Ltd | Healthcare | 15 | up+144.8% | up+231.6% | 1 | up+29.8% | 2.78 | No estimate | |
 OXYGENTAPHLTD Oxygenta Pharmaceutical Ltd | Healthcare | 14 | up+2.1% | down−5.5% | −5 | n/a | −1.33 | No estimate | |
 TYCHEINDUSTRIESLTD | Healthcare | 14 | down−31.1% | up+11.5% | 2 | down−61.9% | 1.48 | No estimate | |
 ACCRETIONNUTRAVEDALTD | Healthcare | 14 | n/a | n/a | 2 | n/a | 4.38 | No estimate | |
 Goldline Pharmaceutical Ltd | Healthcare | 14 | n/a | n/a | 1 | n/a | 1.97 | No estimate | |
| Perk Pharmaceuticals Ltd | Healthcare | 14 | up+67.5% | up+16.4% | 1 | up+171.4% | 0.86 | No estimate | |
 BIOFILCHEM Biofil Chemicals & Pharmaceuticals Ltd | Healthcare | 14 | up+461.8% | up+110.6% | 0 | up+300.0% | 0.05 | No estimate | |
 CENTENIALSURGICALSUTURELTD | Healthcare | 13 | down−5.7% | up+4.0% | 0 | down−107.7% | −0.03 | No estimate | |
 VIVOBIOT Vivo Bio Tech Ltd | Healthcare | 13 | up+8.9% | up+4.8% | 1 | down−83.4% | 0.39 | No estimate | |
 GUJARATTERCELABORATORIESLTD | Healthcare | 13 | down−2.8% | up+19.2% | 1 | down−5.4% | 1.89 | No estimate | |
 JEEVANSCIENTIFICTECHNOLOGYLTD | Healthcare | 12 | up+8.6% | up+40.7% | 0 | down−96.0% | −0.06 | No estimate | |
 RAJNISHWELLNESSLTD | Healthcare | 12 | down−31.1% | up+163.2% | 0 | down−78.6% | 0.00 | No estimate | |
 ZENOTECHLABORATORIESLTD | Healthcare | 11 | up+14.9% | up+16.5% | −1 | down−162.2% | −0.14 | No estimate | |
 CONCORDDRUGSLTD | Healthcare | 10 | down−14.9% | down−24.7% | 0 | up+280.0% | 0.19 | No estimate | |
 VILINBIO Vilin Bio Med Ltd | Healthcare | 10 | up+115.1% | n/a | 0 | up+25.0% | 0.11 | No estimate | |
| Solvay Pharma India Ltd(merged) | Healthcare | 9 | down−12.7% | down−45.7% | −4 | n/a | −2.57 | No estimate | |
 AUROLABORATORIESLTD | Healthcare | 9 | up+185.2% | up+219.1% | 1 | up+100.0% | 1.16 | No estimate | |
 VASUNDHARARASAYANSLTD | Healthcare | 9 | down−9.8% | up+16.7% | 2 | up+40.1% | 6.48 | No estimate | |
 PHARMAIDSPHARMACEUTICALSLTD | Healthcare | 9 | up+64.3% | up+29.3% | −3 | n/a | −0.71 | No estimate | |
 SPARC Sun Pharma Advanced Research Company Ltd | Healthcare | 8 | down−38.5% | down−20.0% | −76 | n/a | −2.34 | No estimate | |
 Span Divergent Ltd | Healthcare | 8 | up+173.2% | up+615.0% | 0 | down−460.0% | −0.24 | No estimate | |
 FABINOLTD Fabino Enterprises Ltd | Healthcare | 7 | up+56.0% | n/a | 0 | down−733.3% | −0.90 | No estimate | |
 KMSMEDISURGILTD | Healthcare | 7 | down−15.2% | n/a | 0 | up+187.5% | 0.70 | No estimate | |
 SHREEPACETRONIXLTD | Healthcare | 7 | up+63.1% | up+23.4% | 1 | up+4,266.7% | 3.64 | No estimate | |
 GKB GKB Ophthalmics Ltd | Healthcare | 6 | down−26.0% | down−30.3% | −1 | n/a | −1.03 | No estimate | |
 SHUKRAPHAR Shukra Pharmaceuticals Ltd | Healthcare | 6 | 0.0% | up+20.0% | 2 | up+100.0% | 0.05 | No estimate | |
 BERYLDRUGSLTD | Healthcare | 5 | down−8.5% | up+6.8% | 0 | 0.0% | 0.02 | No estimate | |
 BRAWNPHARMACEUTICALSLTD Brawn Biotech Ltd | Healthcare | 5 | up+48.2% | down−15.7% | 0 | n/a | 0.23 | No estimate | |
 DECIPHERLABSLTD | Healthcare | 4 | down−26.6% | up+47.6% | 0 | n/a | 0.02 | No estimate | |
 UNJHAFORMULATIONSLTD | Healthcare | 4 | up+13.5% | up+18.2% | 1 | n/a | 1.83 | No estimate | |
 KREBSBIO Krebs Biochemicals & Industries Ltd | Healthcare | 4 | down−67.6% | down−23.9% | −6 | n/a | −2.85 | No estimate | |
 VEERHEALTHCARELTD | Healthcare | 4 | down−22.7% | down−11.4% | 0 | down−16.7% | 0.13 | No estimate | |
 ISHITADRUGSINDUSLTD Ishita Drugs & Industries Ltd | Healthcare | 3 | down−6.1% | down−43.1% | 0 | down−26.3% | 0.47 | No estimate | |
 LASA Lasa Supergenerics Ltd | Healthcare | 3 | down−92.2% | down−84.7% | −6 | n/a | −1.25 | No estimate | |
| Sangam Health Care Products Ltd | Healthcare | 3 | down−16.0% | up+7.8% | 0 | up+228.6% | 0.15 | No estimate | |
 ACHYUTHEALTHCARELTD | Healthcare | 3 | n/a | down−17.5% | 0 | n/a | 0.01 | No estimate | |
 PARMAXPHARMALTD | Healthcare | 3 | down−72.7% | up+30.4% | −2 | n/a | −5.56 | No estimate | |
 MEDINOVADIAGNOSTICSERVICELTD Medinova Diagnostic Services Ltd | Healthcare | 3 | down−2.3% | down−8.1% | 1 | up+2.0% | 0.51 | No estimate | |
| Medinova Diagnostic Services Ltd | Healthcare | 3 | down−2.3% | down−8.1% | 1 | up+2.0% | 0.51 | No estimate | |
 ZENITHHEALTHCARELTD | Healthcare | 2 | down−25.1% | down−27.9% | 0 | up+55.6% | 0.03 | No estimate | |
 GUJINJECLTD Gujarat Inject (Kerala) Ltd | Healthcare | 2 | down−81.6% | down−34.7% | 0 | down−88.5% | 0.00 | No estimate | |
 VISTAPHARMACEUTICALSLTD | Healthcare | 1 | down−41.4% | down−3.9% | −3 | n/a | −0.42 | No estimate | |
 COLINZLABORATORIESLTD | Healthcare | 1 | down−25.3% | down−11.5% | 0 | down−12.5% | 0.56 | No estimate | |
 GANGAPHARMACEUTICALSLTD | Healthcare | 1 | up+4.6% | n/a | 0 | 0.0% | 0.03 | No estimate | |
| VENMAXDRUGSPHARMACEUTICALSLTD Venmax Drugs & Pharmaceuticals Ltd | Healthcare | 1 | up+676.5% | up+9.1% | 0 | n/a | 0.02 | No estimate | |
 MEDICAPQ Medi Caps Ltd | Healthcare | 1 | up+2.0% | n/a | 0 | down−35.6% | 0.23 | No estimate | |
 NECLIFE Nectar Lifescience Ltd | Healthcare | 1 | down−83.3% | down−80.0% | −176 | down−3,033.3% | −7.85 | No estimate | |
 SUVEN Suven Life Sciences Ltd | Healthcare | 1 | down−66.7% | down−50.0% | −77 | n/a | −3.40 | No estimate | |
 DESHRAKSHAKAUSHDHALAYALTD | Healthcare | 1 | down−20.2% | down−26.9% | 0 | down−46.7% | 0.14 | No estimate | |
 AMBALALSA Ambalal Sarabhai Enterprises Ltd | Healthcare | 1 | n/a | down−51.8% | 0 | down−108.8% | −0.05 | No estimate | |
 SHREEGANESHBIOTECHINDIALTD | Healthcare | 1 | down−61.1% | down−44.2% | 0 | down−96.9% | 0.00 | No estimate | |
 CHEMOPHARMALABORATORIESLTD Starsource Multitrade Ltd | Healthcare | 1 | n/a | n/a | 0 | down−83.6% | 0.67 | No estimate | |
 VANTABIOSCIENCELTD | Healthcare | 0 | down−70.9% | n/a | −2 | n/a | −2.56 | No estimate | |
| REKVINALABORATORIESLTD Rekvina Labs Ltd | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.02 | No estimate | |
 TRANSPACTENTERPRISESLTD | Healthcare | 0 | n/a | n/a | 0 | n/a | 1.29 | No estimate | |
 GENOMICVALLEYBIOTECHLTD | Healthcare | 0 | down−57.1% | 0.0% | 0 | down−100.0% | 0.00 | No estimate | |
 SHYAMAINFOLTD Shyama Computronics and Services Ltd | Healthcare | 0 | up+16.7% | 0.0% | 0 | up+150.0% | 0.05 | No estimate | |
| RAYMEDLABSLTD Cresanto Global Limited | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.02 | No estimate | |
 ORTINGLOBE Ortin Global Ltd | Healthcare | 0 | down−80.0% | down−87.5% | −1 | n/a | −0.61 | No estimate | |
 TRANSCHEMLTD | Healthcare | 0 | n/a | n/a | 1 | down−52.8% | 0.56 | No estimate | |
 TRIOCHEMPRODUCTSLTD | Healthcare | 0 | n/a | n/a | 0 | n/a | −7.76 | No estimate | |
| GENESISIBRCINDIALTD CCME Global Ltd | Healthcare | 0 | down−100.0% | n/a | 0 | down−101.6% | −0.05 | No estimate | |
 BACILPHARMALTD | Healthcare | 0 | n/a | n/a | 0 | down−97.9% | 0.01 | No estimate | |
 KAMRONLABORATORIESLTD Adline Chem Lab Ltd | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.12 | No estimate | |
| MPS Pharmaa Ltd | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.12 | No estimate | |
 TAKE Take Ltd | Healthcare | 0 | n/a | n/a | 6 | n/a | 0.43 | No estimate | |
 Transchem Ltd | Healthcare | 0 | n/a | n/a | 1 | down−52.8% | 0.56 | No estimate | |
| Harleystreet Pharmaceuticals Ltd(merged) | Healthcare | — | n/a | n/a | 184 | up+18.7% | 5.84 | No estimate | |
About Q2 FY26 earnings data
When are Q2 FY26 results announced?
Q2 FY26 covers the Jul–Sep 2025 quarter. Indian listed companies have up to 45 days after a quarter closes to file their results — 60 days for the January–March quarter — so results arrive in a wave over the weeks that follow rather than all at once. A quarter that has only just ended will look sparse and fill in.
Why do some Q2 FY26 growth figures show "n/a" instead of a percentage?
Growth is left blank whenever the comparison period was not profitable. A percentage change measured from a loss is arithmetic without meaning — a swing from a ₹10 crore loss to a ₹10 crore profit is not "200% growth", and publishing it as such would flatter the company. The reported figures for both periods are still shown, so the change is there to read directly.
Does the beat/miss verdict cover every company?
No, and the denominator matters. An analyst consensus existed for 245 of the 6,052 companies that reported Q2 FY26 — 4.0%. Beat, missed and in-line describe only those. Every other company is marked "no estimate" rather than being counted as in line, because nobody forecast it. Revenue and profit growth, by contrast, cover every company in the table.
What counts as an in-line result rather than a beat or a miss?
Reported earnings per share within ±2% of the consensus estimate. The band is set there because a tighter one classifies rounding as news, and a wider one swallows surprises that genuinely moved a stock.
Are the figures consolidated or standalone?
Consolidated where a company reports on that basis, standalone otherwise, with all money in ₹ crore. Figures are as filed by the company with the exchanges (NSE/BSE); they are not restated or adjusted.
What does the 8-quarter trend line show?
Quarterly net profit for the last eight quarters, oldest on the left, always ending on the quarter shown in the row. Two years covers both the seasonal shape of the business and its direction. The line breaks where a quarter is missing rather than drawing across the gap, so a break is a real absence of data and not a reported collapse.
How do I find only the companies that beat estimates in Q2 FY26?
Use the Result filter above the table and choose Beat, or sort by EPS surprise to rank every covered company by how far it landed from consensus. Both are reflected in the page URL, so a filtered view can be bookmarked or shared.
Figures are as reported by companies in their quarterly filings to the exchanges (NSE/BSE), in ₹ crore. Consolidated results are shown where a company reports them, otherwise standalone. Year-on-year and quarter-on-quarter growth is omitted where the comparison period was loss-making, since a percentage change from a negative base is not meaningful. Analyst consensus is an estimate, not a forecast of outcome.